肺泡表面活性物质预防新生儿呼吸窘迫综合征的疗效被引量：12

The effect of pulmonary surfactant prevention of neonatal respiratory distress syndrome

导出

摘要目的:探讨肺泡表面活性物质(PS)预防新生儿呼吸窘迫综合征(NRDS)的疗效及其安全性。方法:回顾性分析本院2008年2月～2010年10月收治入院的早产儿120例的临床资料,随机将120例早产儿分为研究组60例和对照组60例,研究组气管插管后气囊加压同时直接注入肺泡表面活性物质,注入后拨管,然后低流量吸氧支持治疗。对照组是呼吸机支持下注入肺泡表面活性物质,上机3～7d后拨管。观察两组NRDS发病率、并发症发生率和病死率。结果:研究组和对照组RDS发生率、CPAP使用率、并发症发生率及病死率与对照组比较差异均有统计学意义(P<0.05)。结论:PS可明显减少NRDS的发生率,减少CPAP的使用及并发症的发生,改善患儿预后。呼吸机支持下注入肺泡表面活性物质的方式较好。 Objective：To investigate the efficacy and safety for pulmonary surfactant（PS） prevention of neonatal respiratory distress syndrome（NRDS）.Methods：Aretrospective analyzed our hospital premature children from February 2008 to October 2010 admitted to hospital clinical data of 120 cases,120 cases were randomly divided into study group with 60 preterm children and control group with 60 cases,the study group injected directly into the bag after intubation while pressurized pulmonary surfactant,extrbated after injected,and then to support low-flow oxygen therapy.The control group was injected into the pulmonary surfactant under the ventilator support,pulled out the trachea on the machine control 3-7 days after.Observed the NRDS incidence,morbidity and mortalityincidence of the two groups.Results：The control group compared with the control group were significantly different in the incidence of RDS and CPAP usage,complications and mortality（P0.05）.Conclusion：PS can significantly reduce the incidence of NRDS,the use of CPAP to reduce the incidence of complications and improve prognosis in children.Ventilator support into the surfactant is as a good way.

作者郭德康

机构地区广东省东莞市人民医院儿科

出处《中国当代医药》 2011年第14期56-57,共2页 China Modern Medicine

关键词肺泡表面活性物质预防新生儿呼吸窘迫综合征疗效 Pulmonary surfactant Prevention Neonatal respiratory distress syndrome Effectiveness

分类号 R722.6 [医药卫生—儿科]

引文网络
相关文献

参考文献4

1李耘,吕回,卫巧贤.早产儿呼吸机相关性肺炎病原菌分析[J].中国实用儿科杂志,2003,18(8):472-474. 被引量：48
2刘珊,周晓光.肺表面活性物质治疗新生儿呼吸窘迫综合征的临床体会[J].新生儿科杂志,1999,14(3):126-128. 被引量：8
3刘江勤,林振浪.肺表面活性物质早期给药对新生儿呼吸窘迫综合征的影响[J].新生儿科杂志,2004,19(5):210-213. 被引量：12
4王莹,马雅玲,张巍.肺表面活性物质预防早产儿RDS的临床观察[J].新生儿科杂志,2004,19(4):148-151. 被引量：27

二级参考文献15

1Yu JL, Wu SX, Jia HQ. Study on autimicrobial susceptibility of bacteria causing neonatal infections: a 12 years study (1987 -1998). Sinapore Med J, 2001,42(5): 107.
2Fanos V, Verlato G, Dal Moro A, et al. Staphylococens epidermidis isolation and antibiotic resistance in a neonatal intensive care unit. J Chemther, 1995,7(1) : 26.
3Stevens TP, Blennow M, Soil RF. Early suffactant administration with brief ventilation vs selective suffactant and continued mechanical ventilation for preterm infants with or at risk for RDS. Cochrane Database Syst Rev, 2002,(2):CD003063.
4Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev, 2000, (2) :CD000511.
5Suresh GK, Soil RF. Exogenous surfactant therapy in newborn infants. Ann Acad Med Singapore, 2003,32(3):335-45.
6Plavka R, Kopecky P, Sebron V, et al. Early versus delayed surfactant administration in extremely premature neonates with respiratory distress syndrome ventilated by high- frequency oscillatory ventilation. Intensive Care Med, 2002,28(10) : 1483-90.
7Yost CC, Soil RF. Early versus delayed selective surfactant treatment for neonatal respiratory, distress syndrome. Cochrane Database Syst Rev, 2000, (2) : CD001456.
8Gonda TA, Hutchins GM Surfactant treatment may accalerate epithelial cell regeneration in hyaline membrane disease of the newborn. Am J Perinatol, 1998,15(9) :539 - 44.
9Brown DR, Bloom BT Cohen M,et al. Increased survival in low birth weight neonates given prophylactic surfactant. J Perinatol,1998,18(6) :431 - 435.
10Shimada S, Kasai T, Hoshi A, et al. Cardiocirculatory effects of patent ductus arteriosus in extremely low - birth - weight infants with respiratory distress syndrome. Pediatr Int, 2003,45(3) :255 - 262.